Ramipril Capsules USP 2.5 mg, a) 90 count (NDC 68180-589-09), b) 100 count NDC 68180-589-01), and c) 500 count (NDC 68180-589-02) bottles, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, Manufactured by Lupin Limited, Goa, India
Published November 27, 2024 · Recall initiated: October 23, 2024
Summary
FDA records drug Class II recall D-0052-2025, published November 27, 2024 and initiated October 23, 2024. Recalling firm: Lupin Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 112,770 bottles; Lot: a) NDC 68180-589-09; Lots G326781, exp. date 30-Sep-25, GA04468, exp. date 31-May-25 b) NDC 68180-589-01; Lots G326763, exp. date 30-Sep-25, GA03041, exp. date 31-Mar-26, GA03725, exp. date 30-Apr-26, GA04402, exp. date 31-May-26, c) NDC 68180-589-02; Lots G326782, exp. date 30-Sep-25, GA04462, exp. date 31-May-26. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor
What to do
Voluntary: Firm initiated · Letter
Get an email if RAMIPRIL has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- RAMIPRIL
- Manufacturer
- Lupin Pharmaceuticals Inc.
- Distributor
- Product was distributed to 30 wholesalers/distributors who may have further distributed the product nationwide.
- UPC
- 0368180591092
- Lot
- a) NDC 68180-589-09; Lots G326781, exp. date 30-Sep-25, GA04468, exp. date 31-May-25 b) NDC 68180-589-01; Lots G326763, exp. date 30-Sep-25, GA03041, exp. date 31-Mar-26, GA03725, exp. date 30-Apr-26, GA04402, exp. date 31-May-26, c) NDC 68180-589-02; Lots G326782, exp. date 30-Sep-25, GA04462, exp. date 31-May-26
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDARamipril Capsules USP, 10 mg, packaged in a) 100 Capsules (NDC 76282-673-01) and b) 500 Capsules (NDCSeptember 2, 2026
- FDARamipril Capsules USP 10 mg, a) 90 count (NDC 68180-591-09), b) 100 count NDC 68180-591-01), and c) 500 countNovember 27, 2024
- FDARamipril Capsules USP 5 mg, a) 90 count (NDC 68180-590-09), b) 100 count NDC 68180-590-01), and c) 500 countNovember 27, 2024
- FDABEVACIZUMAB (AVASTIN)1.25mg/0.05mL, Sterile Injection, 0.5 mL Single-Dose Syringe, Rx Only, Repackaged by:November 27, 2024
- FDAGuaifenesin Dextromethorphan Syrup, 100 mg/10mg per 5 mL, Major Pharmaceuticals 8401 Bearing Drive, Suite 100,November 27, 2024
- FDAGuaifenesin Dextromethorphan Syrup, 200 mg/20mg per 10 mL, Major Pharmaceuticals 8401 Bearing Drive, SuiteNovember 27, 2024
Questions about this recall
Was Ramipril Capsules USP 2.5 mg, a) 90 count (NDC 68180-589-09), b) 100 count NDC 68180-589-01), and c) 500 count (NDC 68180-589-02) bottles, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, Manufactured by Lupin Limited, Goa, India recalled?
Yes. FDA published recall D-0052-2025 on November 27, 2024. Reported hazard: CGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendor
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: RAMIPRIL. UPC: 0368180591092.